Home › NDC Lookup › Ingredients › Guaifenesin And Pseudoephedrine Hydrochl... › 00536-1333-21
⚪image loading
(from DailyMed)

Guaifenesin D Guaifenesin and Pseudoephedrine Hydrochloride 600 mg; 60 mg Tablet, Extended Release, 18-count — NDC 0536-1333-21 (Billing 00536-1333-21)

by RUGBY LABORATORIES, INC. · 1 BLISTER PACK in 1 CARTON / 18 TABLET, EXTENDED RELEASE in 1 BLISTER PACK

This is a package of 18 tablets of Guaifenesin D Guaifenesin and Pseudoephedrine Hydrochloride 600 mg; 60 mg Tablet, Extended Release from RUGBY LABORATORIES, INC., marketed since Apr 2022 and currently FDA-listed, this package's marketing is listed to end Mar 2027; retail pharmacies pay about $0.3841 per tablet (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 00536-1333-21
🏷️ FDA NDC (as labeled) 0536-1333-21 billing pads the labeler segment with a zero
This package
Contains18-count Cost per ea$0.3841 NADAC Per package$6.91 / 18 tablets Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.6327/unit — full pricing hub ↓
Main listing for product 0536-1333 · Also comes in: 18 tablets 0536-1333-36
OTC Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0536-1333-21
Product NDC 0536-1333
11-digit billing NDC 00536133321
NCPDP billing unit EA — each (per item)
RxCUI 1305603
UNII 495W7451VQ, 6V9V2RYJ8N
Application # ANDA212542
SPL Set ID 997946e6-eff0-4c15-8694-020a19c2d336
Established class (EPC) Expectorant
Physiologic effect Decreased Respiratory Secretion Viscosity; Increased Respiratory Secretions
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2022-04-04
Marketing end 2027-03-31
Route ORAL
Dosage form TABLET, EXTENDED RELEASE
Substance GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 43996202307435
GPI class Pseudoephedrine-guaiFENesin ER
GCN Seq No 012073
GCN 54980
HICL code 000270
Ingredient (HICL) Guaifenesin/Pseudoephedrne Hcl
HIC1 code B
Therapeutic class — broad (HIC1) Respiratory System
HIC2 code B4
Therapeutic class — intermediate (HIC2) Drugs Affecting The Trachea And Bronchi (Contin.1)
HIC3 code B4W
Therapeutic class — specific (HIC3) Decongestant-Expectorant Combinations
AHFS code 12:12.12.00
AHFS class Alpha- And Beta-Adrenergic Agonists
FDB label name GUAIFENESIN-PSE ER 600-60 MG
FDB brand name Guaifenesin-Pseudoephedrine Er
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 012073
  • GCN: 54980
  • GPI-14 (Medi-Span): 43996202307435
  • HICL (First Databank): 000270
  • AHFS class code: 12:12.12.00
  • RxCUI (RxNorm): 1305603
Why two NDCs? The FDA registers this code as 0536-1333-21 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00536-1333-21. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Expectorant class.

Pharmacologic class Expectorant
Drug family (ATC) Expectorants
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name GUAIFENESIN-PSE ER 600-60 MG Ingredient Guaifenesin/Pseudoephedrne Hcl
📖 What it is MedlinePlus · NLM

Guaifenesin is used to relieve chest congestion. Guaifenesin may help control symptoms but does not treat the cause of symptoms or speed recovery. Guaifenesin is in a class of medications called expectorants. It works by thinning the mucus in the air passages to make it easier to cough up the mucus and clear the airways.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It helps loosen chest mucus so your cough is more productive. It also temporarily relieves nasal and sinus congestion from a cold, hay fever or other upper respiratory allergies.
  • Swallow them whole with a full glass of water. Don't crush, chew or break them. You can take them with or without food, and they're usually taken about every 12 hours. Follow the p...
  • How should I take the extended-release tablets?
  • Be careful here. If your medicine is an MAOI, you shouldn't take this product, or for 2 weeks after stopping the MAOI. If you aren't sure what your prescription is, ask me before y...
📖 Read our full Guaifenesin / Pseudoephedrine guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.384 $6.91 / 18 tablets
Medicaid paysCMS SDUD · 12 mo $0.6327 $11.39 / 18 tablets
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Apr 2022 Jan 2024 Mar 2026 Sep 2026 $0.462 $0.310
▼ Down 17% over the last 17 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00536-1333-21 You're viewing this Main listing 1 BLISTER PACK in 1 CARTON / 18 TABLET, EXTENDED RELEASE in 1 BLISTER PACK $0.3841 / ea $6.91 2022-04-04 Mar 31, 2027 Active
00536-1333-36 0536-1333-36 2 BLISTER PACK in 1 CARTON / 18 TABLET, EXTENDED RELEASE in 1 BLISTER PACK $0.3841 / ea $13.83 2022-04-04 Mar 31, 2027 Active

This pack has the lowest per-ea cost of the 2 priced pack sizes ($0.3841 NADAC).

This pack accounts for about 44% of this product's recent Medicaid fills; most go to a different pack size. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 18-count package — 1 blister pack in 1 carton / 18 tablet, extended release in 1 blister pack.
What NDC number is used to bill for this package of Guaifenesin D Guaifenesin and Pseudoephedrine Hydrochloride 600 mg; 60 mg Tablet, Extended Release?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Guaifenesin and Pseudoephedrine HCl 600 mg/1; 60 mg 70677-1011-01 Strategic 18 tablets $0.357 — FDA listed save 7%
mucus D 600 mg/1; 60 mg 00113-8307-68 L. 18 tablets $0.384 — Availability likely —
Guaifenesin D 600 mg/1; 60 mgthis 00536-1333-21 RUGBY 18 tablets $0.384 — Availability likely —
Rugby Mucus Relief D 600 mg/1; 60 mg 00536-1449-21 Rugby 18 tablets $0.384 — Availability likely —
Leader Mucus Relief D 600 mg/1; 60 mg 70000-0720-01 Cardinal 18 tablets $0.384 — Availability likely —
Guaifenesin and Pseudoephedrine HCl 600 mg/1; 60 mg 70677-1263-01 Strategic 18 tablets $0.384 — Availability likely —
foster and thrive mucus relief d 600 mg/1; 60 mg 70677-1272-01 Strategic 18 tablets $0.384 — Availability likely —
Mucinex D 600 mg/1; 60 mg 63824-0057-18 Reckitt 18 tablets $0.704 — FDA listed +83%
Guaifenesin and Pseudoephedrine Hydrochloride 600 mg/1; 60 mg 00363-0077-18 WALGREEN 18 tablets — — FDA listed —
Mucus Relief D 600 mg/1; 60 mg 00363-1604-15 Walgreens 18 tablets — — FDA listed —
Mucus Relief D 600 mg/1; 60 mg 00363-8708-68 Walgreen 18 tablets — — FDA listed —
Guaifenesin D 600 mg/1; 60 mg 00363-9930-18 Walgreen 18 tablets — — FDA listed —
Guaifenesin and Pseudoephedrine HCl 600 mg/1; 60 mg 00363-9946-40 WALGREEN 18 tablets — — FDA listed —
Guaifenesin and Pseudoephedrine HCl 600 mg/1; 60 mg 11822-0046-01 Rite 18 tablets — — FDA listed —
Guaifenesin and Pseudoephedrine HCl 600 mg/1; 60 mg 30142-0137-12 KROGER 18 tablets — — FDA listed —
mucus d 600 mg/1; 60 mg 30142-0739-68 Kroger 18 tablets — — FDA listed —
Guaifenesin and Pseudoephedrine Hydrochloride 600 mg/1; 60 mg 41415-0994-18 PUBLIX 18 tablets — — FDA listed —
Guaifenesin and Pseudoephedrine HCl 600 mg/1; 60 mg 46122-0801-08 Amerisource 18 tablets — — FDA listed —
Mucinex D 600 mg/1; 60 mg 50090-1075-00 A-S 18 tablets — — FDA listed —
Mucinex D 600 mg/1; 60 mg 50090-1076-00 A-S 9 tablets — — FDA listed —
Mucus D 600 mg/1; 60 mg 51316-0878-68 CVS 18 tablets — — FDA listed —
Guaifenesin D 600 mg/1; 60 mg 51316-0993-18 CVS 18 tablets — — FDA listed —
Guaifenesin and Pseudoephedrine HCl 600 mg/1; 60 mg 51660-0074-18 Ohm 18 tablets — — FDA listed —
Guaifenesin and Pseudoephedrine HCL 600 mg/1; 60 mg 55111-0798-09 Dr. 9 tablets — — FDA listed —
Guaifenesin and Pseudoephedrine HCl 600 mg/1; 60 mg 58602-0833-12 Aurohealth 18 tablets — — FDA listed —
mucus relief d 600 mg/1; 60 mg 59640-0621-89 H 18 tablets — — FDA listed —
Guaifenesin and Pseudoephedrine Hydrochloride 600 mg/1; 60 mg 62011-0475-01 STRATEGIC 18 tablets — — FDA listed —
Guaifenesin and Pseudoephedrine HCl 600 mg/1; 60 mg 62207-0827-72 Granules 10 tablets — — FDA listed —
Mucus D 600 mg/1; 60 mg 69842-0095-18 CVS 18 tablets — — FDA listed —
Mucus D 600 mg/1; 60 mg 79481-0709-01 Meijer, 18 tablets — — FDA listed —
Guaifenesin and Pseudoephedrine HCl 600 mg/1; 60 mg 79481-1002-01 Meijer 18 tablets — — FDA listed —
equate mucus d 600 mg/1; 60 mg 79903-0125-18 WALMART 18 tablets — — Discontinued —
topcare mucus d 600 mg/1; 60 mg 76162-0801-89 Topco 1 tablet — — FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2022
On the market since
Apr 2022
📍
2026
Currently FDA-listed
4 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerRUGBY LABORATORIES, INC.
Application holderSUN PHARMACEUTICAL INDUSTRIES INC
FDA applicationANDA212542 (ANDA)
Labeler code00536
First marketedApr 2022
Product typeHuman Otc Drug
Portfolio14 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 📦 Storage and Handling 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Do Not Use 📄 Ask a Doctor Before Use If 📄 When Using This Product 📄 Stop Use and Ask a Doctor If 🤰 If Pregnant or Breast-Feeding 📄 Keep Out of Reach of Children 📄 Questions or Comments 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 53 words ▾

Uses helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive temporarily relieves nasal congestion due to: common cold hay fever upper respiratory allergies temporarily restores freer breathing through the nose promotes nasal and/or sinus drainage temporarily relieves sinus congestion and pressure

⏱️ Dosage and Administration 58 words ▾

Directions do not crush, chew, or break extended-release tablet take with a full glass of water this product can be administered without regard for timing of meals adults and children 12 years and older: 2 extended-release tablets every 12 hours; not more than 4 extended-release tablets in 24 hours children under 12 years of age: do not use

⚠️ Warnings 183 words ▾

Warnings Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product. Ask a doctor before use if you have heart disease high blood pressure thyroid disease diabetes trouble urinating due to an enlarged prostate gland persistent or chronic cough such as occurs with smoking, asthma, chronic bronchitis, or emphysema cough accompanied by too much phlegm (mucus) When using this product do not use more than directed Stop use and ask a doctor if you get nervous, dizzy, or sleepless symptoms do not get better within 7 days, come back or occur with a fever, rash, or persistent headache.

These could be signs of a serious illness. If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children.

In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).

📦 Storage and Handling 25 words ▾

Other information Tamper evident: Do not use if carton is open or if printed seal on blister is broken or missing. store between 20-25°C (68-77°F)

🧪 Active Ingredient 17 words ▾

Active ingredients (in each extended-release tablet) Purposes Guaifenesin 600 mg Expectorant Pseudoephedrine HCl 60 mg Nasal Decongestant

🧪 Inactive Ingredients 13 words ▾

Inactive ingredients carbomer homopolymer, NF; hypromellose, USP; magnesium stearate, NF; microcrystalline cellulose, NF

🎯 Purpose 17 words ▾

Active ingredients (in each extended-release tablet) Purposes Guaifenesin 600 mg Expectorant Pseudoephedrine HCl 60 mg Nasal Decongestant

📄 Do Not Use 55 words ▾

Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product.

📄 Ask a Doctor Before Use If 45 words ▾

Ask a doctor before use if you have heart disease high blood pressure thyroid disease diabetes trouble urinating due to an enlarged prostate gland persistent or chronic cough such as occurs with smoking, asthma, chronic bronchitis, or emphysema cough accompanied by too much phlegm (mucus)

📄 When Using This Product 10 words ▾

When using this product do not use more than directed

📄 Stop Use and Ask a Doctor If 40 words ▾

Stop use and ask a doctor if you get nervous, dizzy, or sleepless symptoms do not get better within 7 days, come back or occur with a fever, rash, or persistent headache. These could be signs of a serious illness.

🤰 If Pregnant or Breast-Feeding 10 words ▾

If pregnant or breast-feeding, ask a health professional before use.

📄 Keep Out of Reach of Children 22 words ▾

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).

📄 Questions or Comments 25 words ▾

Questions? call toll-free Monday to Friday 8:30 am to 5:00 pm EST at 1-800-645-2158 . You may also report side effects to this phone number.

📄 Package Label / Principal Display Panel 70 words ▾

PRINCIPAL DISPLAY PANEL - 36 Tablet Blister Pack Carton Rugby ® NDC 0536-1333-36 Compare to the active ingredients in Mucinex ® D † Guaifenesin and Pseudoephedrine HCl Extended-Release Tablets Guaifenesin 600 mg Pseudoephedrine HCl 60 mg 600 mg/60 mg Expectorant and Nasal Decongestant 12 Hour Clears Nasal/Sinus Congestion Thins and Loosens Mucus Immediate and Extended Release Actual Size 36 Extended-Release Tablets PRINCIPAL DISPLAY PANEL - 36 Tablet Blister Pack Carton

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
716
Units reimbursed last 4 qtrs
17K
Gross reimbursed last 4 qtrs
$10.7K
Avg / prescription
$14.99
Avg / unit
$0.6327
Latest quarter Q1 2026
72Rx
Medicaid pays / ea
$0.6327
gross reimbursed
vs
NADAC / ea
$0.3841
acquisition cost
=
Spread
+$0.2486
+65% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
46% FFS 54% MCO
Fee-for-service · 332 Rx Managed care · 384 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 8,385 units · 42.8 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: 2,392 units · 20.3 per 100k residents OH Pennsylvania: 1,704 units · 13.1 per 100k residents PA New Jersey: 276 units · 3.0 per 100k residents NJ Massachusetts: no data reported MA California: no data reported CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: 2,618 units · 57.8 per 100k residents KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: 220 units · 3.6 per 100k residents MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: 474 units · 6.4 per 100k residents AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 891 units · 2.9 per 100k residents TX Florida: no data reported FL
Units reimbursed · per 100k residents
2.957.8
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Kentucky 57.8 /100k
2 New York 42.8 /100k
3 Ohio 20.3 /100k
4 Pennsylvania 13.1 /100k
5 Arizona 6.4 /100k
6 Maryland 3.6 /100k
7 New Jersey 3.0 /100k
8 Texas 2.9 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
18 tablets00536-1333-36 913 Rx · $14,325
18 tablets this page00536-1333-21 716 Rx · $10,730
Drug total (last 4 qtrs): 1,629 Rx · 43,367 units · $25,055 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Guaifenesin D (this brand).

Top reported reactions

Death4
Myocardial Infarction4
Pain4
Anxiety3
Cholecystitis Chronic3
Deep Vein Thrombosis3
Injury3

Reporter sex

0 reports
Male · 15%
Female · 85%
Reports over time (by year) — tap or hover for the count & year
2020 2022 2024 2026 1 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
← 00536-1332-15 · RUGBY 00536-1334-34 · RUGBY →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.